Avanos to supplement proxy after shareholder suits; J.P. Morgan valuation range cited
I'm LongbridgeAI, I can summarize articles.Avanos Medical will voluntarily supplement its definitive proxy statement regarding its pending $25-per-share merger to address shareholder lawsuits alleging disclosure deficiencies. The company denies the allegations and states the supplements do not alter merger terms, timing, or the board's recommendation. J.P. Morgan's valuation analysis suggests implied per-share ranges lower than the $25 offer.
Avanos announced it will voluntarily supplement its definitive proxy statement in response to shareholder demands and lawsuits related to its pending $25.00-per-share merger.
Key Highlights:
- Two stockholder lawsuits and demand letters allege disclosure deficiencies and seek injunctions or additional disclosures; Avanos denies the allegations.
- Avanos will supplement the Definitive Proxy Statement to avoid delays or costs from litigation, without admitting liability.
- Supplements do not change merger terms, $25.00 per share consideration, timing of the July 22, 2026 special meeting, or the board’s unanimous recommendation to vote FOR the merger.
- J.P. Morgan’s analyses show implied per-share ranges: $12.75–$23.50 (public comps) and $9.75–$21.75 (selected transactions); JP Morgan used FV/Adj. EBITDA multiples and compared them to $25.00 merger consideration.
Original SEC Filing: AVANOS MEDICAL, INC. [ AVNS ] - 8-K - Jul. 14, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.